Electra Therapeutics raises $350M in biotech IPO, fueling rare disease drug development

Electra Therapeutics completed a $350 million initial public offering, becoming the 21st biotechnology company to go public in 2026. The strong demand for its shares highlights continued investor appetite for clinical‑stage biotech firms.

The company plans to allocate the proceeds to advance ipsoprubart, an experimental therapy for secondary hemophagocytic lymphohistiocytosis (HLH), a rare immune disorder with no approved treatments. The drug is currently in a registrational trial, with enrollment expected to finish in the second half of 2027.

Electra's IPO adds to a broader trend this year, as eleven biotech companies have each raised more than $300 million, matching the total seen in 2021 and exceeding the combined totals of the previous four years. All of these firms, including Electra, have at least one drug in human testing, underscoring the market's confidence in early‑stage therapeutic pipelines.